PresseBox
Pressemitteilung BoxID: 755452 (Lophius Biosciences GmbH)
  • Lophius Biosciences GmbH
  • Am BioPark 13
  • 93053 Regensburg
  • http://www.lophius.de
  • Ansprechpartner
  • Robert Phelps
  • +49 (941) 6309197-80

Lophius Biosciences Closed Financing to Further Strengthen Marketing and Sales

(PresseBox) (Regensburg, Germany, ) Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell based research tools and diagnostics for functional assessment of pathogen/disease-reactive T cells, today announced the successful completion its financing round with its current syndicate of investors. The round was led by VRD GmbH (Heidelberg) with S-Refit AG (Regensburg, Germany), Wolf Biotech GmbH (Starnberg, Germany), Bayern Kapital (Landshut, Germany) and High-Tech Gründerfonds GmbH (Bonn, Germany) participating.

Proceeds from this round of financing will be used to further strengthen the commercialization and expansion of existing diagnostic kits as well as of the portfolio of novel T cell based research tools. “Management and investors are very much looking forward to a further fruitful collaboration and successful company development” Dr. Robert Phelps, Lophius’ Chief Executive Officer said.

Website Promotion

Lophius Biosciences GmbH

Lophius Biosciences GmbH (www.Lophius.com) is a privately held biotech company, focusing on the development and marketing of innovative T cell-based research tools and diagnostic systems for functional assessment of disease-reactive T cells. The Company's flag ship product is T-Track® CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus (CMV) seropositive transplant patients who undergo an immunosuppressive therapy. With its innovative products, the Company aims to significantly improve therapy control and personalized treatment of patients in the area of transplantation medicine, infectious and autoimmune diseases.